Solid Biosciences (SLDB) Receivables (2021)

Solid Biosciences' (SLDB) quarterly Receivables came in at $220000.0 in Q4 2021.

Solid Biosciences (SLDB) Receivables (2021) Analysis & Trends

Solid Biosciences has disclosed Receivables across 1 years of filings, most recently posting $220000.0 for Q4 2021.

Receivables for Q4 2021 came in at $220000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2021 was $220000.0 (changed N/A YoY), and the FY2021 annual result was $220000.0, changed N/A from the prior year.
Receivables came in at $220000.0 for Q4 2021 at Solid Biosciences.
In the past five years, Receivables ranged from a high of $220000.0 in Q4 2021 to a low of $220000.0 in Q4 2021.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-	-
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn	13.10 Mn
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-	-
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-	-
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn	2.00 Bn
9	Abivax	90.15 Bn	90.15 Bn	-	-
10	Solid Biosciences	789.54 Mn	408.86 Mn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2021	220,000.00